<DOC>
	<DOC>NCT00557973</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with spasticity due to spinal cord injury</brief_summary>
	<brief_title>A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury</brief_title>
	<detailed_description>This is a multiple-dose, randomized, placebo-controlled crossover study of the efficacy and safety of XP19986 SR1 in subjects with spasticity due to spinal cord injury. Three cohorts of subjects are randomized to receive XP19986 SR1 10 mg every 12 hrs or 20 mg every 12 hrs or 30 mg every 12 hrs in one treatment segment and placebo every 12 hrs in the alternate treatment segment. Each subject serves as their own control in this cross-over study.</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Arbaclofen placarbil</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>Spasticity secondary to traumatic spinal cord injury between C5 and T12 spinal cord levels, at least 12 months postinjury with a stable neurological deficit Traumatic brain injury or cognitive deficit of any etiology that may influence compliance with study procedures or outcome measures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>